Drug intelligence / Profile preview

VaxcoTeii

Development stage
Unknown
Lead developer
Youfeng Biotechnology
Modality
Peptides, Vaccines & Immunotherapeutics
Administration
Intranasal
01

Overview

VaxcoTeii (also known as COVID-away Nasal Spray) is a peptide-based intranasal spray developed by Youfeng Biotechnology (YoufengBio). It utilizes the proprietary Ii-Key peptide technology, which is designed to enhance the presentation of antigens to the immune system by modulating MHC class II molecules. Specifically, the Ii-Key peptide (a segment of the invariant chain) facilitates the charging of antigenic peptides into the MHC class II binding groove, thereby boosting CD4+ T-cell mediated immune responses. The product is intended for the prevention and treatment of COVID-19 (SARS-CoV-2) and has reported antibacterial activity against *Escherichia coli* and *Staphylococcus aureus*. It is administered intranasally and is positioned as both an antiviral and an antibacterial agent.

Brand names
VaxcoTeiiCOVID-away Nasal Spray
Other names
VaxcoTeii 多肽抑菌喷雾剂peptide antibacterial spray
02

Targets

MHC II (Major histocompatibility complex class II receptor)

Beyond the preview

Go deeper on VaxcoTeii.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on VaxcoTeii.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call